TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* SGA at birth (defined as a length at birth equal or below the tenth percentile according to the Italian reference table of Bertini and Fabris)~* Age of 24 Months~* Caucasic~* Born at term (i.e. after the 37th completed week of gestation)~* Height equal or below (Group A) or up (Group B) the third percentile at the age of 24 months according to the Tanner reference table~* Sufficient GH secretion (more than 10 nanogram (ng)/milliliter (ml)) at least to one of the tests commonly used at that age (glucagon, Levo-dopa, arginine, clonidine, Growth Hormone Releasing Hormone (GHRH), GH integrated secretion)~* Normal level of Thyroid-stimulating hormone (THS), Free Triiodothyronine (FT3), Free Thyroxine (FT4), Insulin-like growth factor 1(IGF-1), insulin and haemoglobin A1c (HbA1c)~* Normal level of Immunoglobulin A (IgA)~* Children parents willing to comply with the protocol for the whole duration of the study~* A written Informed Consent before the baseline visit must be obtained from the parent(s) / legal guardian(s)~Exclusion Criteria:~* Congenital malformations (including Silver-Russel syndrome)~* Known abnormal karyotype, especially in girls~* Twins~* Severe psychomotor retardation~* Previous or ongoing treatment with anabolic steroids or r-hGH~* Treatments interfering with the immune system (including bacterial lysate)~* Severe chronic illnesses~* Autoimmune diseases

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Group A (A1) (Type: EXPERIMENTAL): Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
- Group A (A2) (Type: NO_INTERVENTION): Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
- Group B (Type: NO_INTERVENTION): Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who submitted a written informed consent for the this trial, and 18 \~ 90 years old~* Patient who have pancreatic cancer and/or biliary cancer with mid or distal CBD invasion~* Patient who is inoperable and/or unresectable cases of malignant pancreatic stenosis~* Patient who is attempting of endoscopic biliary metallic stenting (by ERBD) firstly~* Patient who have life expectancy at least longer than 3 months (Karnofsky score \>60%)~Exclusion Criteria:~* Patient who previously had surgical biliary drainage~* Patient who carrying bleeding disorder~* Patient who have combined Hilar and/or intra-hepatic duct cancer~* Patient who is improper to endoscopic treatment

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel Eluting Covered Metal Stent (Type: EXPERIMENTAL): None
- Covered Metal Stent (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Islet of Langerhans Graft Monitoring by Magnetic Resonance Imaging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients on the waiting list for an islet of Langerhans transplantation procedure~Exclusion Criteria:~* Allergy to ferucarbotran~* Inability to undergo MRI (patients carrying osteosynthesis material, pacemakers or other metallic devices)~* Claustrophobia (tolerance to MRI)~* Hemosiderosis/hemochromatosis (interference with MRI signal)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Study subjects (Type: EXPERIMENTAL): One-arm observational study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Free, informed and signed consent~* Person affiliated or beneficiary of a social security system or the Universal Health Coverage~* Female~* No menopausal, aged 18 to 45 years,~* Under oral contraceptive or implant~* Urine pregnancy test negative~* HBsAg and HCV serology negative~* Cervicovaginal smear normal older than one year,~* Normal vaginal smear dated within one year~For healthy women~\* HIV serology negative~For infected women~* HIV-1 infection checked by western-blot and/or the detection of HIV-RNA~* CD4+ T cells \>350/mm3 (several tests, since 6 months)~* Viral load \<40 copies/ml since 6 months~* Treated with antiretroviral drugs since 6 months~Exclusion Criteria:~* Significant history of vaginal pathology (malignancy, prolapse)~* Hysterectomy, conization~* History of abnormal Pap smear in the previous year (ASC-US, AG-US and LSIL and high grade according to Bethesda).~* Breakthrough bleeding;~* Clinical symptoms suggestive of genital infection within 10 days prior to the examination of the study,~* Antibiotic systemically within 10 days prior to the examination of the study,~* Immunosuppressive or immunomodulatory treatment in the last six months and corticosteroids (\> 20 mg / day for 5 days) in last 3 months~* Presence of other sexually transmitted infection detected in samples at pre-inclusion visit and ongoing at V1 visit (Mycoplasma, Chlamydia, gonorrhea, Trichomonas, Candida albicans and Syphilis)~* A person participating in another research including a period of exclusion still ongoing selection~* Population called vulnerable (minors, persons under guardianship, or deprived of liberty by a judicial decision.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Healthy women volunteers (Type: OTHER): Healthy women volunteers with vaginal swabs by washing and cytobrush
- HIV-1 infected women (Type: OTHER): HIV-1 infected women with vaginal swabs by washing and cytobrush

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: CoStar Catheter System Evaluation

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is ≥18 years of age.~2. Eligible for percutaneous coronary intervention (PCI).~3. Documented stable or unstable angina pectoris (Canadian Cardiovascular Society Classification \[CCS\] 1, 2, 3, or 4), documented ischemia, or documented silent ischemia.~4. Left ventricular ejection fraction (LVEF) ≥25% documented within the last 6 weeks.~5. Acceptable candidate for coronary artery bypass graft surgery (CABG).~6. Patient understands the study requirements and the treatment procedures and provides written Informed Consent using a form that has been approved by the local Institutional Review Board or Ethics Committee before any study-specific tests or procedures are performed.~7. Willing to comply with all specified follow-up evaluations.~Inclusion Criteria (Angiographic):~1. A single de novo lesion per study subject may be treated with the study device.~2. Each target lesion may be composed of multiple lesions but must be completely coverable by one (1) study stent.~3. Cumulative target lesion length per vessel is ≤24 mm based on a visual estimate.~4. RVD of ≥2.5 mm to ≤3.0 mm based on a visual estimate.~5. Target lesion diameter stenosis ≥50% and \<100% based on a visual estimate.~6. Target vessel has not undergone prior revascularization within the preceding 6 months.~7. Target lesion must be a minimum of 10 mm distance from any previously treated segment of the target vessel~Exclusion Criteria:~1. Known sensitivity to cobalt chromium, paclitaxel or polymeric matrices: PLGA.~2. Planned treatment with any other PCI device in the target vessel(s).~3. Acute MI within 72 hours prior to the index procedure as defined by the presence of a new pathologic Q wave, or creatinine kinase (CK) \>2 times the laboratory upper limits of normal and elevated MB.~4. The patient is in cardiogenic shock.~5. Cerebrovascular Accident (CVA) within the past 6 months.~6. Acute or chronic renal dysfunction (creatinine \>2.0 mg/dl or \>150 µmol/L).~7. Contraindication to ASA or to clopidogrel.~8. Thrombocytopenia (platelet count \<100, 000/mm3).~9. Active gastrointestinal (GI) bleeding within the past three months.~10. Any prior true anaphylactic reaction to contrast agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- OTW Catheter System (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Panic Disorder Via Internet With a Wireless Temperature Biofeedback Ring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The participant must fulfill DSM-IV criteria for panic disorder.~2. The participant must be between 18 and 60 years of age.~3. The participant must have panic disorder as the primary problem.~4. If the participant is taking prescribed drugs for panic disorder, a) the dosage have to be constant for 2 months before starting treatment, and b) the participant have to agree to keep the dosage constant for 1 month after starting treatment.~5. If the participant was already in therapy, the contact must have lasted at least 6 months and not be based on cognitive behavior therapy.~6. All participants have access to a computer with an Internet connection.~Exclusion Criteria:~1. The participant suffers from any other psychiatric disorder in immediate need of treatment.~2. The participant fulfills DSM-IV criteria for major depression.~3. The participant has epilepsy, kidney problems, strokes, organic brain syndrome, emphysema, heart disorders, or chronic hypertension. 4. The participant has alcoholism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- relaxation (Type: ACTIVE_COMPARATOR): The patients of this arm practice on-line muscle relaxation for 8 weeks.
- relaxation & biofeedback (Type: EXPERIMENTAL): The patients of this arm practice on-line muscle relaxation plus finger temperature biofeedback for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Smartphone Based Screening Tool for Neonatal Jaundice in Surabaya, Indonesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infants born with gestational age \>31~* Birth weight ≥ 1500g~* Age 0 - ≤14 days~* Consent obtained from the parents~Exclusion Criteria:~* Infants born with congenital abnormalities;~* Infants respiratory support;~* Infants suffering from a condition that may alter the skin tissue circulatory system, such as sepsis and heart failure;~* Infants who have received phototherapy in the last 24 hours.

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 14 Days
- Healthy Volunteers: t

Study Arms:
- Enable high qualitative estimation of bilirubin levels in the blood of new-borns (Type: EXPERIMENTAL): In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All patients with Central Nervous System tumors (primary/metastatic) undergoing radiation to whole brain/ partial brain.~2. All techniques of radiotherapy used for treatment delivery including VMAT and IMRT.~3. Fractionation regimes- conventional and hypofractionation.~4. Patients with KPS\> 70, Patients able to communicate regarding the treatment side-effects.~5. Eligible patients willing to be a part of the trial.~6. Patients undergoing radiotherapy with or without concurrent Temozolomide~Exclusion Criteria:~1. Patients who have received prior radiotherapy to scalp.~2. Patients that need to be treated for scalp lesion such as squamous cell carcinomas of scalp.~3. Poor neurological status performance patients who are unable to communicate.~4. Prior co-morbidities/ dermatological conditions predisposing to pre-existent excessive hair fall (including Systemic Lupus Erythematosus, Hypothyroidism, Polycystic Ovarian Disease and similar conditions)~5. Patients unwilling to come for follow-up.~6. Patients who are completely bald.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients (Type: None): Patients undergoing Radiation therapy to brain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Use of LUMA Lightwire

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients needing endoscopic sinus surgery~* initial or previous sinus surgery subject will be included~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Part A: Overtly healthy postmenopausal (PMP) females~* Part B: PMP women who are currently taking oral bisphosphonates for prevention or treatment of osteoporosis~* Have a body mass index (BMI) at screening of 19.0 to 35.0 kilogram per square meter (kg/m\^2)~Exclusion Criteria:~* Have known allergies to blosozumab, its constituents, or related compounds~* Have an abnormality in the 12-lead electrocardiogram (ECG)~* History of breast carcinoma~* Fracture of a long bone within 1 year of screening~* Have used teriparatide within 3 years prior to screening

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Blosozumab Formulation A (Type: EXPERIMENTAL): Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
- Blosozumab Formulation B (Type: EXPERIMENTAL): Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
- Placebo (Type: PLACEBO_COMPARATOR): Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
- Blosozumab (Part B) (Type: EXPERIMENTAL): Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age \> 18~* Histological diagnosis of non small-cell lung cancer (NSCLC)~* Stage IIIb or Stage IV disease (in IIIb, previous treatment with chemotherapy + radiotherapy, or metastatic supraclavicular lymph nodes or pleural effusion)~* Disease in progression~* Previous chemotherapy with platinum-derivative (and with \> 21 days from last administration)~Exclusion Criteria:~* ECOG performance status \> 2~* Age \> 75 years~* History of malignant neoplasm within the previous 5 years (except for baso- or spino-cellular skin carcinoma and in-situ carcinoma of the uterine cervix, provided they are being adequately treated)~* Previous treatment with docetaxel~* Presence of symptomatic cerebral metastasis~* Neutrophils \< 2.0 x 109/l, platelets \< 100,000/l, hemoglobin \> 10g/dl~* Bilirubin \< 1.5 x the upper normal limit~* SGOT , SGPT, or bilirubin \> 1.25 x the upper normal limits except in the presence of hepatic metastasis~* Creatinine \>1.25 x the upper normal limit~* Any concomitant pathology that would, in the Investigator's opinion, contraindicate the use of the drugs in the protocol~* Inability to comply with follow up~* Pregnant or nursing females

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- docetaxel (Type: ACTIVE_COMPARATOR): single agent docetaxel
- docetaxel + vinorelbine OR gemcitabine (Type: EXPERIMENTAL): docetaxel in combination with either vinorelbine or with gemcitabine
- docetaxel + capecitabine (Type: EXPERIMENTAL): docetaxel in combination with capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bupivacaine Plus Diclofenac Versus Bupivacaine Alone for Postoperative Pain Relief in Gynecologic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gynecologic cancer patients ,i.e. cervical cancer, endometrial cancer, or ovarian tumor suspicious for malignancy~* who has scheduled for operation via laparotomy route~* Women who has ASA physical status I-II~* All of the have age more than 20 years old~* able to communicate in Thai~* Women who agrees to participate in this study~Exclusion Criteria:~* patient who had emergency conditions - indication for emergency operation~* intraoperative cardiac arrhythmia~* operation purpose for only tumor biopsy~  * Women who have abnormal kidney function test (Cr \> 1.5)~ * Women with history of gastrointestinal bleeding~ * Women who take the antiplatelet or anticoagulant medications~ * Women with history of allergy to bupivacaine and NSAIDs~ * Women who cannot evaluated pain score

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- diclofenac and bupivacaine group (Type: EXPERIMENTAL): Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
- bupivacaine only group (Type: PLACEBO_COMPARATOR): Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum, divided in 10 sites before closure and a 3 mL of sterile water was intramuscularly injected immediately after complete the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval